アブストラクト
| Title | 2. サクビトリルバルサルタンの特性 2) サクビトリルバルサルタンの作用機序と特徴 |
|---|---|
| Subtitle | 特集 心不全薬物療法の新展開 - サクビトリルバルサルタンの登場 - |
| Authors | 江尻健太郎, 伊藤浩* |
| Authors (kana) | |
| Organization | *岡山大学大学院医歯薬総合研究科循環器内科学 |
| Journal | PROGRESS IN MEDICINE |
| Volume | 41 |
| Number | 4 |
| Page | 355-359 |
| Year/Month | 2021 / 4 |
| Article | 報告 |
| Publisher | ライフ・サイエンス |
| Abstract | 「はじめに」 サクビトリルバルサルタンはアンジオテンシン受容体ネプリライシン阻害薬(angiotensin receptor neprilysin inhibitor: ARNI)であり, 左室駆出率が低下した心不全(HFrEF)に対する治療薬である. ARNIは2015年に欧米でHFrEFに対して認可され, わが国でも2020年に保険収載された比較的新しい薬剤である. 慢性心不全, 特にHFrEFに対する薬物治療はここ数年でARNIをはじめとしてナトリウム・グルコース共輸送体(SGLT)2阻害薬が登場し, 可溶性グアニル酸シクラーゼ刺激薬が市販を控え, 心筋ミオシン活性化薬がHFrEF患者でポジティブな結果が示されたなど, 大きく変化しつつある. HFrEF治療薬が増えた現在, 薬剤選択における薬理作用を理解することの重要性は増している. 本稿ではARNIの薬理作用とその特徴を解説する. |
| Practice | 医学総合 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に968円(税込) です。
参考文献
- 1) Gu J, Noe A, Chandra P, et al : Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNI). J Clin Pharmacol 2010 ; 50 : 401-414.
- 2) Zannad F, Gattis Stough W, Rossignol P, et al : Miner-alocorticoid receptor antagonists for heart failure with reduced ejection fraction : integrating evidence into clinical practice. Eur Heart J 2012 ; 33 : 2782-2795.
- 3) Yancy CW, Jessup M, Bozkurt B, et al : 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure : a re-port of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 2017 ; 136 : e137-e161.
- 4) Yancy CW, Jessup M, Bozkurt B, et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foun-dation/American Heart Association Task Force on practice guidelines. Circulation 2013 ; 128 : e240-e327.
- 5) Mancini GB, Howlett JG, Borer J, et al : Pharmacolog-ic options for the management of systolic heart fail-ure : examining underlying mechanisms. Can J Cardi-ol 2015 ; 31 : 1282-1292.
残りの13件を表示する
- 6) Cleland JG, Swedberg K : Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. Lan-cet 1998 ; 351 : 1657-1658.
- 7) O'Connor CM, Starling RC, Hernandez AF, et al : Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011 : 365 : 32-43.
- 8) Packer M, Califf RM, Konstam MA, et al : Comparison of omapatrilat and enalapril in patients with chronic heart failure : the Omapatrilat Versus Enalapril Ran-domized Trial of Utility in Reducing Events(OVER-TURE). Circulation 2002 ; 106 : 920-926.
- 9) Kostis JB, Packer M, Black HR, et al : Omapatrilat and enalapril in patients with hypertension : the Omapatri-lat Cardiovascular Treatment vs. Enalapril(OC-TAVE) trial. Am J Hypertens 2004 : 17 : 103-111.
- 10) McMurray JJ, Packer M, Desai AS, et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 ; 371 : 993-1004.
- 11) Solomon SD, McMurray JJV, Anand IS, et al : Angio-tensin-neprilysin inhibition in heart failure with pre-served ejection fraction. N Engl J Med 2019 ; 381 : 1609-1620.
- 12) Vardeny O, Claggett B, Kachadourian J, et al : Reduced loop diuretic use in patients taking sacubitril/valsar-tan compared with enalapril : the PARADIGM-HF trial. Eur J Heart Fail 2019 ; 21 : 337-341.
- 13) Velazquez EJ, Morrow DA, DeVore AD, et al : Angio-tensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2018 ; 380 : 539-548.
- 14) Januzzi JL, Jr., Prescott MF, Butler J, et al : Association of change in N-terminal pro-B-type natriuretic pep-tide following initiation of sacubitril-valsartan treat-ment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JA-MA 2019 ; 322 : 1-11.
- 15) Desai AS, Solomon SD, Shah AM, et al : Effect of sacu-bitril-valsartan vs enalapril on aortic stiffness in pa-tients with heart failure and reduced ejection frac-tion : a randomized clinical trial. JAMA 2019 ; 322 : 1-10.
- 16) Habibi J, Aroor AR, Das NA, et al : The combination of a neprilysin inhibitor(sacubitril) and angiotensin-II receptor blocker(valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Cardio-vasc Diabetol 2019 ; 18 : 40.
- 17) Packer M, Claggett B, Lefkowitz MP, et al : Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are re-ceiving target doses of inhibitors of the renin-angio-tensin system : a secondary analysis of the PARA-DIGM-HF trial. Lancet Diabetes Endocrinol 2018 ; 6 : 547-554.
- 18) Seferovic JP, Claggett B, Seidelmann SB, et al : Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes : a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 2017 ; 5 : 333-340.
